sibrotuzumab

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Antibodies, Monoclonal, Humanized

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
FBROBLAST ACTIVATION PROTEIN AND MMUNOCONUGATES CONTAINING THEMI
  • 2017
EP O953639 A1 11, 1999 EP 1258255 A1 11, 2002 WO 99.57151 A2 11/1999 WO O1687.08 A2 9, 2001 WO 02083171 10, 2002 WO 2005060999 A2… (More)
  • figure 5
Is this relevant?
2007
2007
Molecular characterization of sarcomatous change in a granulosa cell tumor.
Sarcomatous transformation of a granulosa cell tumor (GCT) is a rare event. We describe the development of a rapidly progressive… (More)
Is this relevant?
2005
2005
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… (More)
Is this relevant?
2004
2004
Population Pharmacokinetics of Sibrotuzumab, A Novel Therapeutic Monoclonal Antibody, in Cancer Patients
Population pharmacokinetics of sibrotuzumab, a humanized monoclonal antibody directed against fibroblast activation protein, were… (More)
Is this relevant?
2004
2004
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
PURPOSE The purpose of this research was to determine the safety, immunogenicity, pharmacokinetics, biodistribution, and tumor… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer.
BACKGROUND A novel immunological approach to colon cancer therapy is the antibody targeting of the fibroblast activation protein… (More)
Is this relevant?
2003
2003
A Phase I Dose-Escalation Study of Sibrotuzumab in Patients with Advanced or Metastatic Fibroblast Activation Protein-positive Cancer 1
Purpose: The purpose of this research was to determine the safety, immunogenicity, pharmacokinetics, biodistribution, and tumor… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2003
2003
Cancer Res . , 9 : 1639 Metastatic Fibroblast Activation Protein-positive Cancer . Study of Sibrotuzumab in Patients with Advanced or Dose-EscalationCommentary re : A .
 
  • figure 1
Is this relevant?
2003
2003
Tumors and their microenvironments: tilling the soil. Commentary re: A. M. Scott et al., A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation…
The conventional concept of tumor-host interactions is rooted in the realm of parasitology. A tumor invades an unsuspecting host… (More)
Is this relevant?